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Abstract
Background: Several studies have addressed the epidemiology of community-associated Staphylococcus aureus (CA-SA) in
Europe; nonetheless, a comprehensive perspective remains unclear. In this study, we aimed to describe the population
structure of CA-SA and to shed light on the origin of methicillin-resistant S. aureus (MRSA) in this continent.
Methods and Findings: A total of 568 colonization and infection isolates, comprising both MRSA and methicillin-susceptible
S. aureus (MSSA), were recovered in 16 European countries, from community and community-onset infections. The genetic
background of isolates was characterized by molecular typing techniques (spa typing, pulsed-field gel electrophoresis and
multilocus sequence typing) and the presence of PVL and ACME was tested by PCR. MRSA were further characterized by
SCCmec typing. We found that 59% of all isolates were associated with community-associated clones. Most MRSA were
related with USA300 (ST8-IVa and variants) (40%), followed by the European clone (ST80-IVc and derivatives) (28%) and the
Taiwan clone (ST59-IVa and related clonal types) (15%). A total of 83% of MRSA carried Panton-Valentine leukocidin (PVL)
and 14% carried the arginine catabolic mobile element (ACME). Surprisingly, we found a high genetic diversity among MRSA
clonal types (ST-SCCmec), Simpson’s index of diversity=0.852 (0.788–0.916). Specifically, about half of the isolates carried
novel associations between genetic background and SCCmec. Analysis by BURP showed that some CA-MSSA and CA-MRSA
isolates were highly related, suggesting a probable local acquisition/loss of SCCmec.
Conclusions: Our results imply that CA-MRSA origin, epidemiology and population structure in Europe is very dissimilar
from that of USA.
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Introduction
Staphylococcus aureus, particularly methicillin-resistant S. aureus
(MRSA) is one of the most important nosocomial pathogens.
Resistance to methicillin is conferred by the mecA gene, which is
carried within a mobile genetic element called staphylococcal
cassette chromosome mec (SCCmec) [1]. So far, eleven major
structural types of SCCmec have been described [2,3,4,5].
For several decades, MRSA was confined to hospitals, but in the
early 1990s, infections in healthy individuals emerged among
Aborigines’ communities in Australia [6]. However, clinical
significance was attributed to these strains only some years later
when four children with no previous hospital contact died in the
USA due to MRSA infection [7]. Although the very first outbreaks
of serious infections in the USA were caused by the USA400 clone
(ST1-IVa) [7], USA300 (ST8-IVa) rapidly become the dominant
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Molecular typing studies showed that CA-MRSA differs from
hospital-associated MRSA (HA-MRSA) [9]: they belong to
distinct genetic lineages, usually carry smaller SCCmec cassettes
and specific virulence factors, such as PVL (Panton-Valentine
leukocidin) and ACME (arginine catabolic mobile element). CA-
MRSA were also shown to have higher expression levels of toxins,
PSMs (phenol soluble modulins) and hemolysins [10,11], suggest-
ing that these isolates are more virulent than HA-MRSA.
Previous studies have shown that USA300 is extremely
widespread in the USA [8,12], whereas CA-MRSA infections in
other parts of the world are generally caused by other clones: the
Southwest-Pacific clone (ST30-IVc) and the Queensland clone
(ST93-IVa) [13,14] in Australia and New Zealand; the Taiwan
clone (ST59-IVa, ST59-V) and USA700 (ST72-IVc) in Asia
[15,16,17]; ST88-IV in Africa [18] and the European clone
(ST80-IVc) in Europe [19]. The dominant CA-MRSA clones in
different European countries have been identified
[20,21,22,23,24,25,26,27,28,29,30]. Nonetheless, the comprehen-
sive population structure of CA-MRSA and MSSA has never been
assessed in Europe. In this study we aim to identify the main CA-
MRSA and MSSA clonal lineages in Europe, to determine its
population structure and to try to shed some light on the origin of
CA-MRSA in this continent.
Methods
Ethical Statement
Isolates were obtained as part of routine diagnostic testing and
were analyzed anonymously and the isolates, not humans, were
studied. All data was collected in accordance with the European
Parliament and Council decision for the epidemiological surveil-
lance and control of communicable disease in the European
community [31,32]. Ethical approval and informed consent were
thus not required.
Bacterial Collection
The collection analyzed in this study was not part of a
structured survey with pre-defined criteria of isolate collection. It
was a convenience sample composed of 568 S. aureus isolates
obtained from infection (74%) and colonization (17%) of patients
attending health-care centers and hospitals, collected within 48
hours of hospitalization. The isolates were distributed among 16 of
the most populous countries in Europe, including The Czech
Republic (75 isolates), Spain (52), The Netherlands (49), Greece
(45), United Kingdom (42), Sweden (41), Hungary (40), Bulgaria
(37), Denmark (37), France (34), Poland (26), Romania (24),
Portugal (22), Finland (20), Slovakia (17) and Italy (7). The isolates
were obtained between 2000 and 2010, but the majority have
been collected between 2007 and 2010 (62%). For 9%, no
information on collection year was available. All isolates were
accompanied by a questionnaire with clinical data and with
questions formulated to ascertain their origin. The isolates were
grouped according with their presumptive origin as suggested
previously [8]: isolates were considered as community-associated
S. aureus (CA-SA) when they were collected from persons that had
no previous contact with the hospital one year before sampling or
any of the assessed risk factors for MRSA carriage and were
obtained in the first 48 hours of hospitalization (Center for Disease
Control criteria); isolates were considered to be community onset
S. aureus (CO-SA) when they were collected from persons with at
least one risk factor for health-care contact although they were
obtained within the first 48 hours of hospitalization. For some of
the isolates no information was available regarding several of the
assessed risk factors for hospital contact. In these cases isolates
were considered as having a community-onset origin.
Patient Population
The patient population included 231 females and 264 males; for
73 patients, no information was available regarding gender. A total
of 122 children (0–18 years), 285 adults (19–64) and 119 elderly
(.65) were included in the study; no information was available
regarding age for 42 patients. The clinical diagnosis for a great
part of the patients (52%) was skin and soft tissue infections
(SSTIs), bacteremia or septicemia (6%), endocarditis (5%),
pneumonia (4%) and urinary tract infections (3%). For 30%, no
information regarding clinical diagnosis was available.
S. aureus Isolation and Cultivation
S. aureus were isolated by standard techniques and identified by
Vitek (Vitek2, bioMe ´rieux, Marcy L’Etoile, France) or phenotypic
methods in participating institutions. Species identification was
confirmed by growth on mannitol salt agar (MSA, Difco, BBL,
Becton Dickinson, Franklin Lakes, New Jersey, USA) and by
testing coagulase production by Staphytec Plus assay (Oxoid,
Cambridge, United Kingdom).
Antimicrobial Susceptibility Testing
All isolates were tested by Vitek (Vitek 2, bioMe ´rieux, Marcy
L’Etoile, France, cards P563, 580, 592, 619), by disk diffusion or
broth microdilution methods, according to the Clinical and
Laboratory Standards Institute recommendations [33] in the
collaborating centers against a panel of 22 antimicrobial agents,
including: oxacillin, benzylpenicillin, cefoxitin, vancomycin, teico-
planin, linezolid, gentamicin, tobramycin, norfloxacin, ciproflox-
acin, levofloxacin, moxifloxacin, erythromycin, clindamycin,
quinupristin/dalfopristin, tetracycline, rifampicin, fosfomycin,
mupirocin, fusidic acid, trimethoprim/sulfamethoxazole, nitrofu-
rantoin. For 157 isolates (28%) the antibiogram was not
performed. Multiresistance was defined as resistance to three or
more classes of antimicrobial agents. The rates of resistance and
multidrug resistance of CA epidemic clones were calculated
considering as denominator the total number of isolates with
antimicrobial susceptibility testing data.
Detection of the mecA and Panton-Valentine Leukocidin
(PVL) Genes
The mecA and lukS-PV, lukF-PV genes (which encode PVL) were
detected as described before [34,35].
SCCmec Typing
The structure of the staphylococcal cassette chromosome mec
(SCCmec) was determined by the updated multiplex PCR strategy
developed by Milheiric ¸o et al [36]. The subtypes of SCCmec type
IV were determined by multiplex PCR as previously described
[37]. In case of ambiguous results this characterization was further
complemented by amplification of the mec complex and ccr
complexes by PCR [9,38,39] and by sequencing an internal region
of the ccrB gene [39,40]. SCCmec was classified according to the
guidelines proposed by the International Working Group on the
Classification of SCC elements [2]. A SCCmec was considered
non-typable (NT) when it was not possible to ascertain a class of
mec complex and/or a type of ccr.
spa Typing
spa typing was performed as previously described [41] and spa
types were attributed using the RIDOM web server (http://
CA-MRSA in Europe
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clonal complexes (spa-CC) [42]. The spa server was used as well to
predict sequence types (STs).
Pulsed-field Gel Electrophoresis (PFGE)
PFGE was performed: 1) to predict STs, when a single ST could
not be inferred from the spa type; 2) to discern the most closely
related clonal type among MSSA strains, when this could not be
deduced from ST (e.g. ST8-MSSA, could be related to USA300
clone or Irish clone (ST8-II)). Total DNA was restricted with SmaI
and the resulting fragments were separated by PFGE as described
before [43]. The SmaI restriction band assignments were
manually curated after automatically band detection, using the
Bionumerics software (Applied Maths, Saint-Martens-Latem,
Belgium). For band patterns comparison with reference strains
belonging to epidemic clones of nosocomial and community
origin, the following settings were used: optimization of 0.50% and
a tolerance of 1.25%. PFGE types were defined by groups formed
at 80% Dice similarity cutoff on a dendrogram constructed by the
unweigthed pair group method using average linkage (UPGMA),
as previously described [40].
Multilocus Sequence Typing (MLST)
MLST was performed when a sequence type (ST) could not be
inferred from the spa type in the spa server (http://spaserver.
ridom.de/) or from the literature. The genetic background of the
isolates was determined by MLST [44]. STs were attributed by
submitting the DNA sequences obtained to the online MLST
database (http://www.mlst.net/). The goeBURST algorithm was
used to assign MLST clonal complexes, CC (http://goeburst.
phyloviz.net). This analysis was performed on October 20
th, 2011.
ACME Detection
The two loci (arc and opp3) that compose ACME-I in USA300
strain FPR3757, were amplified by PCR as previously suggested
[45]. This element was typed according with its structure: type I
(arc and opp3 operons), type II (arc operon only) and type III (opp3
operon only) [45,46]. ACME was detected only in the isolates that
were related with community-associated clones (see below).
Definition of CA-MSSA/CA-MRSA Epidemic Clones and
CA-MRSA/CA-MSSA Clone-related
Community-associated (CA), hospital-associated (HA) and live
stock-associated (LA) epidemic clones were defined as clones
(MSSA:ST; MRSA:ST-SCCmec) previously described to cause
infections in several different geographic locations and that have
originated in the community, hospital and animals, respectively
[47]. In this study, MSSA clones were defined by its ST, spa type,
PFGE type (when necessary), ACME and PVL. Each MRSA
clone was defined based on the association of ST and SCCmec type
as previously proposed [44], as well as by spa type, ACME and
PVL. A clone was considered to be related to other if they shared
all these characteristics except one. For ST, only single locus
variants were considered related. When the molecular character-
istics of an isolate did not fulfill these criteria, the isolate was
considered sporadic.
Assessment of Genetic Diversity
The degree of genetic diversity was assessed by the Simpson’s
index of diversity (SID), using a confidence interval of 95% [48].
The SID was estimated by the combination of the results obtained
by spa typing, PVL and ACME determination (each different
combination was considered a ‘‘type’’ or a ‘‘species’’).
Results
Population Structure of S. aureus Isolated from the
Community-associated Setting
A total of 246 isolates (43%) out of the 568 isolates analyzed in
this study were isolated from subjects with no recent hospital
contact (CDC criteria for CA-SA). The combination of the results
obtained by all the typing methods used showed that the majority
(145 isolates, 59%) was related to epidemic community-associated
(CA) clones, while 67 (27%) were related to hospital-associated
(HA) clones and 32 (13%) were sporadic [47]. In addition, we
recovered two MSSA isolates (1%) belonging to livestock-
associated clones or related (ST398 and its SLV, ST291) (Table 1).
Of the 67 S. aureus isolates belonging to HA clones, 43 were
MRSA and were related with EMRSA15 (ST22-IVh) (19 isolates,
46%), EMRSA-3 (ST5-I) (11 isolates, 24%), and Pediatric (ST5-
VI/IV) (six isolates, 15%) clones. The remaining seven isolates
belonged to New York Japan (ST5-II, 3 isolates), Berlin (ST45-IV),
Brazilian (ST239-III), ST111-I, and ST125-V (one isolate each).
The 24 MSSA isolates belonged to ST45 (10 isolates, 43%), ST5
(seven isolates, 26%), ST22 (five isolates, 22%) and ST36 (two
isolates, 9%).
Of the 145 isolates belonging to CA epidemic clones, 58%
(84 isolates) were MRSA and belonged or were related to USA300
(29 isolates, 37%) and the European epidemic clones (28 isolates,
36%). The remaining isolates belonged to: the Taiwan or related
clones, ST59-V, ST59-IVa (four isolates each, 11%), and a ST59
SLV, ST375-IVa (three isolates); ST772-V (five isolates); ST1-IVa
(three isolates); ST97-IVa (two isolates); ST15-IVa, ST30-IVa,
ST30-IVc, ST72-IVc, ST93-IVa, and ST188-IVa (one isolate
each).
Noteworthy, we observed that a considerable part of the isolates
related to epidemic CA-MRSA clones lacked one or more of their
typical characteristics, namely the presence of PVL and/or ACME
or did not belong to a particular spa type or ST (Table 2 and
Information S1). For example, only 11 isolates out of the 29
isolates related to USA300 had all the molecular characteristics of
this clone (ST8-IVa, t008, PVL+ and ACME-I) [12] and 23 out of
28 isolates had all the characteristics of the European clone (ST80-
IVc, t044, PVL+) [49]. Overall a high genetic diversity of MRSA
clones, as determined by the combination of the results obtained
by spa typing, PVL and ACME determination, was observed
[SID=0.852 (0.788–0.916)].
Among the 61 MSSA that belonged to CA epidemic clones and
were collected from persons with no recent hospital contact, the
most frequent clone was identified as ST30 (12 isolates), followed
by ST121 (11 isolates), but ten additional STs were also identified:
ST1, ST7, ST8 ST15, ST25, ST59, ST80, ST97, ST1472 and
ST1595 (a SLV of ST25). Overall a higher genetic diversity was
observed among MSSA than among MRSA [SID= 0.977 (0.966–
0.989)].
Population Structure of S. aureus Isolated from the
Community-onset Setting
A total of 322 isolates (57%) out of the 568 analyzed in this
study were collected in the first 48 hours of hospitalization from
patients with at least one risk factor for hospital contact, and were
considered as community-onset S. aureus.
Of the 322 isolates, 193 (60%) belonged or were related with
community-associated epidemic clones, 85 (26%) were related to
hospital-associated epidemic clones and 42 (13%) were sporadic.
In addition, we identified two isolates (1%) that belonged to LA-
MRSA epidemic clones (ST398-IVa and ST398-VII) (Table 1).
CA-MRSA in Europe
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but belonging to HA epidemic clones, 43 were MRSA and 42
were MSSA. The most frequent clones among MRSA were E-
MRSA15 (ST22-IVh, 24 isolates, 56%), followed by the Pediatric
(ST5-IV/VI, seven isolates, 16%) and EMRSA 3 (ST5-I, five
isolates, 12%). In addition, we also found the Berlin clone (ST45-
IV, four isolates), New York/Japan (two isolates) and USA500
(ST8-IV, one isolate). The following clones were found among
MSSA: ST45 (20 isolates, 48%), ST5 (15 isolates, 36%) and ST22
(seven isolates, 16%).
Of the 193 isolates belonging or related to community-
associated epidemic clones, 96 (50%) were MRSA. Overall, the
population structure of CA-MRSA and CO-MRSA isolates was
similar. As observed for CA-MRSA isolates, the most frequent
clones among CO-MRSA were USA300-related and the Europe-
an related clone. Other clones that were common in the two
populations were the Taiwan clone (ST59-IVa), the Southwest
Pacific-related clone (ST30-IV), the Queensland clone (ST93-IVa)
and ST97-IVa. However, we also found clones that were only
prevalent among the onset isolate collection, like a SLV of
Taiwan-clone, ST338-V, ST7-IVa, ST7-V, ST1-V and ST1835-
V (Table 3). Overall CO-MRSA showed a genetic diversity similar
to that observed for CA-MRSA isolates as defined by the
combination of spa types with the presence of PVL and ACME
[SID=0.897 (0.863–0. 931)].
Concerning the 97 CO-MSSA isolates, we observed that its
population structure differed from that found for the group of
community-associated isolates analyzed in this study. The
Table 1. Distribution of the isolates analyzed in this study.
Isolate collection/risk factor for hospital
contact
Total no of
isolates
Infection/colonization (no of
isolates) MSSA/MRSA
Type of epidemic clones (no
of isolates,%)
,48 h with risk factor (CO-MRSA/MSSA) 322 225/46* 172/150 CA (193, 60%); HA (85, 26%); LA
(2, 1%); Sporadic (42, 13%)
,48 h with no risk factors (CA-MRSA/MSSA) 246 198/48 107/139 CA (145, 59%); HA (67, 13%); LA
(2, 1%); Sporadic (32, 13%)
*for 51 isolates no information was available regarding this specific question.
doi:10.1371/journal.pone.0034768.t001
Table 2. Molecular characteristics of the 338 CA and CO-S. aureus isolates analyzed in this study that belonged to epidemic CA
clones or related.
Genetic background
(no of isolates; %)
Sequence types
(MLST) SCCmec types spa types
PVL (no positive
isolates/
total isolates)
ACME (no positive
isolates/
total isolates)
CC8 (92; 27) ST8, ST72, ST931,
ST939
IVa, IVc, IVd, IVg,
IVnt, V, VI, NT
t008, t024, t064, t148, t121, t324, t664, t791,
t1189, t1578, t5160, t1705
59/72 40/72
ST8, ST72 MSSA t008, t024, t126, t148, t3682, t5896 2/20 1/20
CC15 (57; 17) ST1, ST15, T188,
ST772, ST1835
IVa, V, NT t084, t127, t189, t345, t657, t1381, t4915 8/13 –
ST1, ST15, ST772,
ST1867
MSSA t084, t085, t121, t127, t184, t273, t346, t368,
t393, t491, t590, t774, t803, t1387, t1492, t2574
9/44 –
CC80 (55; 16) ST80 IVc, IVnt t044, t067, t131, t376 48/51 –
ST80 MSSA t044, t131, t934 4/4 –
CC30 (46; 14) ST30, ST1456 IVc t019, t1133, t7709 8/9 –
ST30, ST34 ST1472,
ST1833
MSSA t012, t018, t021, t032, t037, t122, t136, t238,
t318, t342, t433, t665, t710, t871, t2509, t4275
6/37 –
CC59 (31; 9) ST59, ST338, ST375 IVa, V t172, t216, t437, t441 20/27 5/27
ST59, ST375 MSSA t216, t316, t437 –
CC121 (18; 6) ST121 MSSA t159, t2019, t272, t284, t435, t1114, t4685,
t6031, t645, t6870, t6872
7/18 –
CC7 (18; 5) ST7 IVa, V t091 1/2 –
ST7 MSSA t091, t796, t7710 – –
CC97 (10; 3) ST97 IVa t267 – –
ST97 MSSA t1965, t267, t3380, t359 – –
CC25 (8; 2) ST25, ST1595 MSSA t078, t081, t280, t2909, t3644, t9040 1/8 –
S93 (3; 1) ST93 IVa t202, t1819 3/3 –
NT- non typable.
Clonal complexes (CC) were assigned by applying the e-BURST algorithm to the data obtained in this study and comparing it with the entire MLST database (www.mlst.
net). This analysis was performed on October 20th 2011.
doi:10.1371/journal.pone.0034768.t002
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ST15 and related STs) were different from those identified among
CA isolates. Moreover, we observed that although all clonal types
found among CA isolates were also present in the CO collection,
there were some clonal types that in our study were specific of the
onset setting, namely ST34, ST72, ST1833 and ST1867 (Table 3).
However, this was not translated into a higher genetic diversity
[SID=0.970 (0.957–0.982)].
Clonal Variation and Genetic Diversity Along Time
Although sampling was performed between 2000–2009, the
genetic diversity observed among the two settings was consistent
throughout the entire time-frame analyzed (Information S1). A
slight increase in genetic diversity was observed, particularly from
the first period (2000–2001) to the second one (2002–2003),
though this increase is not statistically significant.
Moreover, we observed that the number of isolates belonging to
each clone varied along time. Whereas the European clone was
the most frequent between 2004 and 2006, the frequency of
USA300 and Taiwan clones increased in the last two years, when
these clones became prevalent (Information S1).
Distribution of PVL, ACME and SCCmec Among S. aureus
Clones
We found an unexpectedly high prevalence of PVL among
community-associated isolates (77/145, 53%) and community-
onset isolates (98/193, 51%). Interestingly, PVL was not limited to
specific genetic backgrounds or clones, but otherwise was found to
be disseminated among all clonal complexes identified among CA
epidemic clones with the exception of CC97.
The great majority of the PVL-positive isolates were MRSA
(83%, 146 out of 175 isolates) and belonged to USA300 clone and
its variants, the European clone and its variants and the Taiwan
clone and related clones. Moreover, PVL genes were identified in
eight additional clones (ST1-IVa, ST7-IVa, ST30-IVc, ST30-IVa,
ST1456-IVc, ST772-V, USA700-ST72-IVc and Queensland-
ST93-IVa) (Table 2 and Information S1). Regarding the 29
MSSA isolates, PVL genes were disseminated among a total of
nine STs, namely ST1, ST8, ST15, ST25, ST30, ST72, ST80,
ST121 and ST1472.
Like for PVL, the distribution of ACME among community-
associated isolates (21/145, 15%) was similar to that found among
community-onset isolates (25/193, 13%) and was mostly associ-
ated to MRSA (45 out of 46 isolates). However, unlike PVL,
ACME distribution was limited only to two clonal complexes
(CC8 and CC59).
ACME-positive isolates belonged or were related to USA300,
the Taiwan clone and USA700. ACME-I was identified
exclusively among USA300-related isolates, while ACME-II,
containing only the arc operon, was identified in isolates of the
other two epidemic clones.
SCCmec typing showed that the great majority of isolates (73 CA
and 73 CO, 81%) carried SCCmec IV, though SCCmec V (28
isolates, 16%) and VI (four isolates, 2%) were also detected. In
addition, two isolates (1%) presented a non-typable SCCmec. The
most common SCCmec IV subtype was SCCmec IVc (78 isolates,
53%), followed by SCCmec IVa (62 isolates, 42%). SCCmec IVd
and IVg were rare (one isolate each) and four isolates carried a
non-subtypable SCCmec IV.
Antibiotic Resistance
As expected, we found a very low rate of antibiotic multi-
resistance in CA-MRSA from both settings, 11.6% (21 isolates out
of 181). The results are summarized in Table 4. Multi-resistance
occurred exclusively in USA300 clone and its variants, in the
European clone, Taiwan and related clones and a ST772-V
isolate. Two isolates resistant to four classes of antimicrobial agents
were identified and belonged to clones ST8-IVc, t024, PVL+ and
ST772-V, t1387, PVL+. Regarding MSSA, antibiotic resistance
rates were extremely low. In fact, only 19.9% (36 isolates out of
181) of the isolates were resistant to at least one class of antibiotics
and a single isolate was identified as multi-drug resistant (0.5%,
ST121, resistant to ciprofloxacin, erythromycin, clindamycin and
tetracycline).
Geographic Distribution of CA-S. aureus in Europe
Overall, a high genetic diversity was found among community-
associated and community-onset S. aureus isolates belonging to CA
epidemic clones (Figure 1). However, some asymmetry was
observed in what respects to the number of different clonal types
found in each country. Whereas in The Netherlands as many as
ten different clonal types were identified among 22 isolates (ST80-
Table 3. Distribution of the 338 MRSA and MSSA isolates
belonging to epidemic CA-MRSA clones or related in the
community and community-onset settings.
Community-associated epidemic clones and related variants (%)
MRSA (52%),
84 isolates
MSSA (48%),
61 isolates
Community-
associated
USA300 and related (35%) ST30 (20%)
European and related (33%) ST121 (18%)
Taiwan and related (13%) ST7 (13%)
ST772-V (6%) ST15 (13%)
ST1-IVa (4%) ST97 (8%)
ST97-IVa (3%) ST80 (7%)
USA700 (1%) ST59 (5%)
ST188-IVa(1%) ST25 (5%)
ST15-IVa (1%) ST1 (3%)
ST30-IVa (1%) ST8 (3%)
ST30-IVc (1%) ST1595 (3%)
ST93-IVa (1%) ST1472 (2%)
MRSA (50%),
96 isolates
MSSA (50%),
97 isolates
Community-onset USA300 and related (42%) ST30 (22%)
European and related (24%) ST15 (21%)
Taiwan and related (17%) ST1 (14%)
Southwest Pacific (5%) ST8 (11%)
USA700 (2%) ST7 (8%)
Queensland (2%) ST121 (7%)
ST1456-IVc (2%) ST72 (7%)
ST772-NT(1%) ST25 (3%)
ST7-IVa (1%) ST97 (2%)
ST7-V (1%) ST34 (2%)
ST1-V (1%) ST59 (1%)
ST1835-V (1%) ST1833 (1%)
ST97-IVa (1%) ST1867 (1%)
doi:10.1371/journal.pone.0034768.t003
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IVc, ST398-VII, ST93-IVa, ST97-IVa), in Poland only three
types among 16 isolates were found (ST338-V, ST80-IVc, ST7-
IVa) (Information S1).
In spite of the genetic diversity observed, all the clonal types
identified were disseminated in more than one country and
neighboring countries shared more clonal types than distant
countries. The most epidemic clonal type among MRSA was the
European clone (ST80-IVc) that was found in eleven different
countries, followed by USA300 (ST8-IVa) that was recovered in
nine countries.
Interestingly, some specificity was observed in what respects the
distribution of the most prevalent clones. Whereas USA300, the
European or related clones were the most prevalent in Southern
and Central European countries, in Northern Europe (Finland,
Sweden and Poland) the most prevalent MRSA clonal type was
related with the Taiwan clone (Figure 1 and Information S1).
Regarding MSSA, the most disseminated clone was ST15 and
related clonal types that were identified in eleven different
countries, followed by ST121 and ST30 and its derivatives that
were identified in nine countries each.
CA-MRSA Origin
In order to understand the origin of the CA-MRSA clones
presently circulating in Europe, we analyzed the relatedness of spa
types identified in MSSA and MRSA isolates belonging to the
same clonal lineage by BURP analysis of the spa types (Figure 2).
BURP analysis showed that MRSA and MSSA isolates
belonging to ST8 (CC-t008, CC-t024, CC-1705/1189), ST72
(CC-t148, CC-t148/t3682) and ST59 (CC-t437, CC-t216) or its
SLVs (Figure 2) shared the same or related spa types, suggesting
that CA-MRSA and CA-MSSA isolates belonging to these STs
were closely related.
On the other hand, for MRSA and MSSA isolates from ST30
(CC-t012) and ST93 (CC-t202/t1819) genetic clones no common
or related spa types were found. Regarding isolates belonging to
the European clone, no conclusions could be drawn since only a
small number of MSSA isolates belonging to this specific genetic
background was found in our collection.
Discussion
The recent establishment of CA-MRSA as a leading cause of
infections in healthy individuals is a matter of great concern.
Previous studies that have addressed the epidemiology of this
pathogen indicate that most of the infections are caused by a
limited number of specific clones that in addition seem to be
geographically restricted [19,47,50]. In this study we report for the
first time the population structure of CA-MRSA in Europe and
describe the very high level of genetic diversity and epidemicity of
CA-MRSA clones on this continent.
As many as ten different CA-MRSA clones in a single country
were found. Moreover, several different variants of already
described clonal types were identified, differing in the nucleotide
sequence of housekeeping genes or in the SCC elements content
and virulence genes; several new or rare CA-MRSA clonal types
(ST772-V, ST7-V, ST188-IVa, ST15-IVa, ST375-IVa and
ST338-V) were identified. Similar results were described in studies
conducted in some European countries [51,52,53], but it was
never observed at a global scale. The reason for the large genetic
diversity observed, in contrast to the situation of a single epidemic
CA-MRSA clone described in USA, is not obvious. We suggest
that the multiplicity of cultural and social behaviors and habits
inherent to each European country, namely frequency and
destination of travel, different hygienic habits, infection control
measures and antibiotic prescription and consumption policies
may have shaped the population structure of CA-MRSA on this
continent. Moreover, the geographic proximity of the countries
and the travel habits resultant of tourism and business can also
have had a role on the dissemination of clonal types among the
different European countries.
Interestingly, the most frequent clone detected in the collection
was USA300 or related clones, which contrasts sharply with
previous studies in Europe in which the European clone was found
to be predominant [19]. This represents a changing trend in the
epidemiology of CA-MRSA in Europe. The USA300 clone is well
adapted to the community environment; it carries ACME and
SCCmec IV, which are believed to confer a higher fitness to the
clone [45,46]. Around 33% of all ST8 isolates had all the
characteristics of the USA300 clone, suggesting that this clone was
imported and is becoming well established in Europe. However,
the great majority of ST8 isolates was highly related with USA300,
but lacked one of its typical molecular characteristics or had others
instead (for instance, the presence of SCCmec V or the absence of
PVL). We were able to detect as many as six different SCCmec
(sub) types and nine spa types associated to ST8, indicating that
different sub clones exist in the population structure of this ST.
The high genetic diversity that we found among ST8 isolates was
already observed by others [54,55,56]. The origin of such variants
is unknown. They may have derived from the epidemic USA300
strain imported from the USA and evolved rapidly in Europe in
order to adapt to different selective pressures, namely by
acquiring/losing virulence factors as PVL or antibiotic resistance
determinants as SCCmec. Alternatively, they may have diverged
from a USA300 MSSA ancestor early in time and established as a
different clone in Europe by the acquisition of an SCCmec element.
The finding in our study of MSSA and MRSA isolates belonging
Table 4. Molecular characteristics of multidrug-resistant
MRSA isolates belonging to epidemic community-associated
clones collected in the community and community onset
settings.
Antibiotic Resistance Genetic background (no isolates)
Beta-lactams, Fus acid, Tet ST80-IVc, t044, PVL+, ACME - (2)
ST80-IVc, t131, PVL+, ACME- (1)
ST8-IVc, t024, PVL+, ACME- (1)
ST375-IVa, t172, PVL-, ACME- (1)
ST59-V, t437, PVL+, ACME II (1)
ST59-V, t437, PVL+, ACME – (1)
Beta-lactams, Fus acid, Ery ST80-IVc, t044, PVL+, ACME - (3)
ST80-IVnt, t044, PVL+, ACME – (1)
ST8-IVc, t024, PVL+, ACME – (1)
Beta-lactams, Cipro, Ery ST8-IVa, t008, PVL+, ACME I (3)
ST8-IVc, t008, PVL+, ACME – (1)
Beta-lactams, Tet, Ery ST8-IVc, t024, PVL+, ACME- (1)
ST80-IVc, t044, PVL+, ACME- (1)
ST59-IVa, t437, PVL-, ACME II (1)
Beta-lactams, Ery, Clind, Tet, Fus acid ST8-IVc, t024, PVL+, ACME- (1)
Beta-lactams, Ery, Tet, Gent ST772-V, t1387, PVL+, ACME- (1)
Cipro – ciprofloxacin; Clind – clindamycin; Ery – erythromycin; Fus acid – fusidic
acid; Tet – tetracycline; Gent – gentamicin.
doi:10.1371/journal.pone.0034768.t004
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existence of a European ST8 clone. However, only the whole
genome sequence of these strains will clarify this hypothesis.
Besides ST8, we also found MRSA and MSSA isolates
belonging to ST72 and ST59 that shared the same spa types,
which suggests that these specific genetic backgrounds could have
also emerged recently in Europe by the acquisition of SCCmec in
already established MSSA clones. On the contrary, for ST30 and
ST93 or related clones no common or related spa types were found
between MRSA and MSSA, suggesting that CA-MRSA belonging
to these clones were probably created outside Europe and
imported later.
The continuous evolution of CA-MRSA in Europe could
explain the high level of genetic diversity of SCCmec found among
CA-MRSA belonging to the same ST: by emerging in Europe,
these isolates could have acquired the most common SCCmec in
each specific location. A similar proposition has been made by
Nu ¨bel et al [57] to explain the diversity among ST5 MRSA.
Although our proposition is plausible we cannot disregard the
hypothesis that the different genetic backgrounds were imported as
MRSA and later lost the SCCmec in Europe in the absence of
selective pressure.
The collection analyzed in this study was not part of a
structured survey with pre-defined criteria of isolate collection. It
was a convenience sample composed of isolates collected within 48
hours of hospital admission. Consequently, the number of isolates
obtained was not equal from country to country and the timeframe
of isolation spanned almost 10 years. The inclusion of a low
number of isolates in some countries might have provided an
erroneous picture of the local epidemiology that wrongly
influenced the overall genetic diversity described in this study.
Moreover, due to the long timeframe of sampling, the genetic
diversity observed in this study might be inflated, not reflecting
absolutely the present reality in Europe.
We found an unexpectedly high prevalence of PVL in our
collection (52%) and a high level of dissemination among S. aureus
CA-epidemic clones. To our knowledge, PVL was only rarely
reported among S. aureus collected in Europe [58,59] and was
usually associated with the European clone [19]. However, there
are studies that report an increasing frequency of this leukocidin in
isolates collected in Europe [53,60]. The data that resulted from
our study suggest that PVL frequency in Europe may be
increasing, not only due to the dissemination of PVL positive
epidemic CA-MRSA clones, but also due to de novo acquisition of
phage encoded PVL by different genetic backgrounds. Surveil-
lance measures should be taken in order to detect these leukocidin-
producing isolates, since several studies have indicated a
connection between the existence of PVL and the outcome of
the disease [11,61,62,63,64].
In contrast we found a low frequency of ACME (14%) mainly
associated with the USA300 clone (ST8-IVa). Noteworthy, we
found some isolates related with the Taiwan clone (ST59-V) and
USA700 (ST72-IV) carrying ACME-II. This fact is particularly
relevant if one take into consideration that acquisition of ACME
by already epidemic S. aureus clones may increase their capacity of
dissemination [46].
Figure 1. Prevalence of MRSA and MSSA community-associated clones in Europe. Distribution of the most prevalent MRSA and MSSA
community-associated epidemic and related clones in 16 of the most populous European countries. Each color represents a different clone and
related clonal lineages. A –MRSA; B –MSSA.
doi:10.1371/journal.pone.0034768.g001
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community onset settings were almost identical in what regards to
distribution of the most prevalent clones, however certain clones
were only identified among the onset-population. The results
suggest that a high number of different CA-MRSA clonal types are
at risk of entering hospital environment through the community-
onset population.
In this study we identified a tremendously high level of genetic
diversity among CA-MRSA in Europe as well as a high frequency
of PVL-positive isolates. This scenario poses an unprecedented
challenge not only to diagnostic but also to infection control. The
fast CA-MRSA evolution in Europe demands a continuous
surveillance as a means to help local health-care providers in
designing strategies to detect and control CA-MRSA.
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ical information.
(DOCX)
Acknowledgments
We thank all the collaborators that participated in studies that led to the
isolation of the Staphylococcus aureus strains. CONCORD working group:
Dimitar Nashev, Department of Microbiology, National Center of
Infectious and Parasitic Diseases, Sofia, Bulgaria; Oto Melter, Depart-
ment of Medical Microbiology, 2nd Faculty of Medicine, Charles
University, Prague, Czech Republic; Helena Zemlickova ´, National
Reference Laboratory for Antibiotics, National Institute of Public Health,
Prague, Czech Republic; Marta Fridrichova, National Reference
Laboratory for Antibiotics, National Institute of Public Health, Prague,
Czech Republic; Henrik Westh, Department of Clinical Microbiology,
Hvidovre Hospital, Hvidovre, Denmark; Saara Salmenlinna, Depart-
ment of Infectious Disease Surveillance and Control, National Institute for
Health and Welfare, Helsinki, Finland; Gerard Lina, INSERMU851,
Universite ´ Lyon 1, Hospices Civils de Lyon, Lyon, France; Iris
Spiliopoulou, Department. of Microbiology, School of Medicine,
University of Patras, Patras, Greece; Eleanna Drougka, Department.
of Microbiology, School of Medicine, University of Patras, Patras, Greece;
Katalin Kristo ´f, Division of Clinical Microbiology Diagnostic Labora-
tory, Central Diagnostic Laboratory, Semmelweis University, Budapest,
Hungary; Ferenc Rozgonyi, National STD Diagnostic Laboratory,
Department of Dermatology, Venerology and Dermatooncology, Sem-
melweis University, Budapest, Hungary; Giammarco Raponi, Micro-
biology Section, Dipartimento di Scienze di Sanita’ Pubblica e Malattie
Infettive, Sapienza University Rome, Rome, Italy; Maria Cristina
Ghezzi, Microbiology Section, Dipartimento di Scienze di Sanita’
Pubblica e Malattie Infettive, Sapienza University Rome, Rome, Italy;
Mireille Wulf, Department of Medical Microbiology, Laboratory for
Pathology and Medical Microbiology (PAMM), Veldhoven, The Nether-
lands; Irina Codita, Nosocomial Infections and Antimicrobial Resistance
Reference Laboratory, ‘‘Cantacuzino’’ National Institute of Research-
Development for Microbiology and Immunology, Bucharest, Romania;
Gabriel Ionescu, Nosocomial Infections and Antimicrobial Resistance
Reference Laboratory, ‘‘Cantacuzino’’ National Institute of Research-
Development for Microbiology and Immunology, Bucharest, Romania;
Maria Nica, ‘‘Victor Babes’’ Clinical Hospital of Infectious and Tropical
Figure 2. Analysis of spa typing data obtained for MRSA and MSSA isolates. spa typing data from isolates belonging to epidemic and
related CA-MRSA clones and sporadic isolates collected in the community and community-onset settings was analyzed by BURP (http://spaserver.
ridom.de/, StaphType software v. 1.5, Ridom GmbH, Wu ¨rzburg, Germany). Each spa type identified is depicted with circles. Related spa types are
connected with a black line; resultant clonal complexes are depicted inside orange boxes. The predicted founder of each clonal complex is indicated
in blue and in a larger circle. The size of the circles is proportional to the frequency of the spa type in the population. Each clonal complex (CC) is
defined by the predicted founder spa type or by the spa types it contains. A –MRSA; B – MSSA.
doi:10.1371/journal.pone.0034768.g002
CA-MRSA in Europe
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e34768Diseases, Bucharest, Romania; Anna Lı ´skova ´, Institut Clinical Microbi-
ology Hospital Nitra and St Elisabeth University Bratislava, Slovak
Republic; Patricia Ruiz-Garbajosa, Servicio de Microbiologı ´a and
CIBER en Epidemiologı ´a y Salud Pu ´blica (CIBERESP), Instituto Ramo ´ny
Cajal de Investigacio ´n Sanitaria (IRYCIS) and Hospital Universitario
Ramo ´n y Cajal, Madrid, Spain; Rafael Canto ´n, Servicio de Microbiologı ´a
and CIBER en Epidemiologı ´a y Salud Pu ´blica (CIBERESP), Instituto
Ramo ´n y Cajal de Investigacio ´n Sanitaria (IRYCIS) and Hospital
Universitario Ramo ´n y Cajal, Madrid, Spain; Maria Angeles Dom-
inguez, Microbiology Department, IDIBELL, Hospital Universitaru de
Bellvitge, Barcelona, Spain; Ann Cathrine Petersson, Clinical Micro-
biology, University and Regional Laboratories, Region Ska ˚ne, Lund,
Sweden; Rebecca Walker, Department of Medical Microbiology,
Sandwell and West Birmingham NHS Trust, Birmingham, United
Kingdom; Rich Anderson, Department of Medical Microbiology,
Sandwell and West Birmingham NHS Trust, Birmingham, United
Kingdom; Jenny Andrews, Department of Medical Microbiology,
Sandwell and West Birmingham NHS Trust, Birmingham, United
Kingdom.
Author Contributions
Conceived and designed the experiments: HdL ACF. Performed the
experiments: JR AT-R JE OB NAF AT. Analyzed the data: JR MM JE
HdL. Contributed reagents/materials/analysis tools: HdL WH CON-
CORD working group. Wrote the paper: JR MM. Manuscript revision:
HdL ACF JE WH AT-R OB NAF AT CONCORD working group.
References
1. Katayama Y, Ito T, Hiramatsu K (2000) A new class of genetic element,
Staphylococcus cassette chromosome mec, encodes methicillin resistance in
Staphylococcus aureus. Antimicrob Agents Chemother 44: 1549–1555.
2. International Working Group on the Classification of SCC elements (IWG-
SCC) (2009) Classification of staphylococcal cassette chromosome mec (SCCmec):
guidelines for reporting novel SCCmec elements. Antimicrob Agents Chemother
53: 4961–4967.
3. Li S, Skov RL, Han X, Larsen AR, Larsen J, et al. (2011) Novel types of
staphylococcal cassette chromosome mec elements identified in clonal complex
398 methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Che-
mother 55: 3046–3050.
4. Garcia-Alvarez L, Holden MT, Lindsay H, Webb CR, Brown DF, et al. (2011)
Meticillin-resistant Staphylococcus aureus with a novel mecA homologue in human
and bovine populations in the UK and Denmark: a descriptive study. Lancet
Infect Dis 11: 595–603.
5. Shore AC, Deasy EC, Slickers P, Brennan G, O’Connell B, et al. (2011)
Detection of staphylococcal cassette chromosome mec type XI carrying highly
divergent mecA, mecI, mecR1, blaZ, and ccr genes in human clinical isolates of
clonal complex 130 methicillin-resistant Staphylococcus aureus. Antimicrob Agents
Chemother 55: 3765–3773.
6. Udo EE, Pearman JW, Grubb WB (1993) Genetic analysis of community isolates
of methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect 25:
97–108.
7. CDC (1999) Four pediatric deaths from community-acquired methicillin-
resistant Staphylococcus aureus - Minnesota and North Dakota, 1997–1999. JAMA
282: 1123–1125.
8. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, et al. (2007) Invasive
methicillin-resistant Staphylococcus aureus infections in the United States. JAMA
298: 1763–1771.
9. Okuma K, Iwakawa K, Turnidge JD, Grubb WB, Bell JM, et al. (2002)
Dissemination of new methicillin-resistant Staphylococcus aureus clones in the
community. J Clin Microbiol 40: 4289–94.
10. Deleo FR, Otto M, Kreiswirth BN, Chambers HF (2010) Community-associated
meticillin-resistant Staphylococcus aureus. Lancet 375: 1557–1568.
11. Diep BA, Chan L, Tattevin P, Kajikawa O, Martin TR, et al. (2010)
Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine
leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci U S A
107: 5587–5592.
12. Tenover FC, McDougal MK, Goering RV, Killgore G, Projan SJ, et al. (2006)
Characterization of a strain of community-associated methicillin-resistant
Staphylococcus aureus widely disseminated in the United States. J Clin Microbiol
44: 108–18.
13. Coombs GW, Nimmo GR, Bell JM, Huygens F, O’Brien FG, et al. (2004)
Genetic diversity among community methicillin-resistant Staphylococcus aureus
strains causing outpatient infections in Australia. J Clin Microbiol 42:
4735–4743.
14. Costello ME, Huygens F (2011) Diversity of community acquired MRSA
carrying the PVL gene in Queensland and New South Wales, Australia.
Eur J Clin Microbiol Infect Dis 30: 1163–7.
15. Kawaguchiya M, Urushibara N, Kuwahara O, Ito M, Mise K, et al. (2011)
Molecular characteristics of community-acquired methicillin-resistant Staphylo-
coccus aureus in Hokkaido, northern main island of Japan: identification of
sequence types 6 and 59 Panton-Valentine Leucocidin-positive community-
acquired methicillin-resistant Staphylococcus aureus. Microb Drug Resist 17:
241–250.
16. Huang Y-C, Chen C-J (2011) Community-associated meticillin-resistant
Staphylococcus aureus in children in Taiwan, 2000s. Int J Antimicrob Agents 38:
2–8.
17. Song JH, Hsueh PR, Chung DR, Ko KS, Kang CI, et al. (2011) Spread of
methicillin-resistant Staphylococcus aureus between the community and the
hospitals in Asian countries: an ANSORP study. J Antimicrob Chemother 66:
1061–1069.
18. Ghebremedhin B, Olugbosi MO, Raji AM, Layer F, Bakare RA, et al. (2009)
Emergence of a community-associated methicillin-resistant Staphylococcus aureus
strain with a unique resistance profile in Southwest Nigeria. J Clin Microbiol 47:
2975–2980.
19. Otter JA, French GL (2010) Molecular epidemiology of community-associated
meticillin-resistant Staphylococcus aureus in Europe. Lancet Infect Dis 10: 227–239.
20. Otter JA, French GL (2011) Community-associated meticillin-resistant Staphy-
lococcus aureus strains as a cause of healthcare-associated infection. J Hosp Infect
79: 189–193.
21. Green SM, Marsh P, Ahmad N, Jefferies JM, Clarke SC (2010) Characterization
of community and hospital Staphylococcus aureus isolates in Southampton, UK.
J Med Microbiol 59: 1084–1088.
22. Jappe U, Heuck D, Strommenger B, Wendt C, Werner G, et al. (2008)
Staphylococcus aureus in dermatology outpatients with special emphasis on
community-associated methicillin-resistant strains. J Invest Dermatol 128:
2655–2664.
23. Campanile F, Bongiorno D, Falcone M, Vailati F, Pasticci MB, et al. (2011)
Changing Italian nosocomial-community trends and heteroresistance in
Staphylococcus aureus from bacteremia and endocarditis. Eur J Clin Microbiol
Infect Dis, in press.
24. Larsen AR, Stegger M, Bocher S, Sorum M, Monnet DL, et al. (2009)
Emergence and characterization of community-associated methicillin-resistant
Staphyloccocus aureus infections in Denmark, 1999 to 2006. J Clin Microbiol 47:
73–78.
25. Stam-Bolink EM, Mithoe D, Baas WH, Arends JP, Moller AV (2007) Spread of
a methicillin-resistant Staphylococcus aureus ST80 strain in the community of the
northern Netherlands. Eur J Clin Microbiol Infect Dis 26: 723–727.
26. Balis E, Diacaki C, Tselioti P, Perimeni D, Vourli S, et al. (2007) Community-
acquired pneumonia and bacteremia due to methicillin-resistant Staphylococcus
aureus carrying Panton-Valentine-leukocidin gene in Greece: two case reports
and literature review. J Chemother 19: 703–708.
27. Robert J, Tristan A, Cavalie L, Decousser JW, Bes M, et al. (2011) Panton-
valentine leukocidin-positive and toxic shock syndrome toxin 1-positive
methicillin-resistant Staphylococcus aureus: a French multicenter prospective study
in 2008. Antimicrob Agents Chemother 55: 1734–1739.
28. Cremieux AC, Dumitrescu O, Lina G, Vallee C, Cote JF, et al. (2009) Panton-
Valentine leukocidin enhances the severity of community-associated methicillin-
resistant Staphylococcus aureus rabbit osteomyelitis. PLoS One 4: e7204.
29. Daskalaki M, Rojo P, Marin-Ferrer M, Barrios M, Otero JR, et al. (2010)
Panton-Valentine leukocidin-positive Staphylococcus aureus skin and soft tissue
infections among children in an emergency department in Madrid, Spain. Clin
Microbiol Infect 16: 74–77.
30. Manzur A, Dominguez AM, Pujol M, Gonzalez MP, Limon E, et al. (2008)
Community-acquired methicillin-resistant Staphylococcus aureus infections: an
emerging threat in Spain. Clin Microbiol Infect 14: 377–380.
31. The Europea Parliament, the Council of the EU (1998) Decision number 2119/
98/EC of the European Parliament and of the Council of 24 September 1998:
setting up a network for the epidemiological surveillance and control of
communicable diseases in the community. Official J Eur Communities L268/1.
Available:http://eurlex.europa.eu/LexUriServ/LexUriServ.
do?uri=OJ:L:2000:028:0050:0053:EN:PDF. Accessed 2011 November 14.
32. The European Commission of the European Communities (2000) Commission
decision of 22 December 1999 on the communicable diseases to be progressively
covered by the community network under decision number 2119/98/EC of the
Parliament and of the Council. Official J Eur Communities L 28/50. Available:
http://eurlex.europa.eu/LexUriServ/LexUriServ.
do?uri=CELEX:31998D2119:EN:HTML. Accessed 2011 November 14.
33. Clinical and Laboratory Standards Institute. Performance Standards for
Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement
M100-S19. CLSI, Wayne, PA, USA, 2009).
CA-MRSA in Europe
PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e3476834. Miragaia M, Couto I, de Lencastre H (2005) Genetic diversity among
methicillin-resistant Staphylococcus epidermidis (MRSE). Microb Drug Resist 11:
83–93.
35. Tristan A, Bes M, Meugnier H, Lina G, Bozdogan B, et al. (2007) Global
distribution of Panton-Valentine leukocidin-positive methicillin-resistant Staph-
ylococcus aureus. Emerg Infect Dis 13: 594–600.
36. Milheiric ¸o C, Oliveira DC, de Lencastre H (2007) Update to the multiplex PCR
strategy for assignment of mec element types in Staphylococcus aureus. Antimicrob
Agents Chemother 51: 3374–3377.
37. Milheiric ¸o C, Oliveira DC, de Lencastre H (2007) Multiplex PCR strategy for
subtyping the staphylococcal cassette chromosome mec type IV in methicillin-
resistant Staphylococcus aureus: ‘SCCmec IV multiplex’. J Antimicrob Chemother
60: 42–48.
38. Zhang K, McClure JA, Elsayed S, Louie T, Conly JM (2005) Novel multiplex
PCR assay for characterization and concomitant subtyping of staphylococcal
cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus.
J Clin Microbiol 43: 5026–5033.
39. Oliveira DC, Milheirico C, Vinga S, de Lencastre H (2006) Assessment of allelic
variation in the ccrAB locus in methicillin-resistant Staphylococcus aureus clones.
J Antimicrob Chemother 58: 23–30.
40. Faria NA, Carrico JA, Oliveira DC, Ramirez M, de Lencastre H (2008) Analysis
of typing methods for epidemiological surveillance of both methicillin-resistant
and methicillin-susceptible Staphylococcus aureus strains. J Clin Microbiol 46:
136–144.
41. Aires-de-Sousa M, Boye K, de Lencastre H, Deplano A, Enright MC, et al.
(2006) High interlaboratory reproducibility of DNA sequence-based typing of
bacteria in a multicenter study. J Clin Microbiol 44: 619–621.
42. Mellmann A, Weniger T, Berssenbrugge C, Rothganger J, Sammeth M, et al.
(2007) Based Upon Repeat Pattern (BURP): an algorithm to characterize the
long-term evolution of Staphylococcus aureus populations based on spa polymor-
phisms. BMC Microbiol 7: 98.
43. Chung M, de Lencastre H, Matthews P, Tomasz A, Adamsson I, et al. (2000)
Molecular typing of methicillin-resistant Staphylococcus aureus by pulsed-field gel
electrophoresis: comparison of results obtained in a multilaboratory effort using
identical protocols and MRSA strains. Microb Drug Resist 6: 189–198.
44. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG (2000) Multilocus
sequence typing for characterization of methicillin-resistant and methicillin-
susceptible clones of Staphylococcus aureus. J Clin Microbiol 38: 1008–1015.
45. Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, et al. (2006) Complete
genome sequence of USA300, an epidemic clone of community-acquired
meticillin-resistant Staphylococcus aureus. Lancet 367: 731–739.
46. Diep BA, Stone GG, Basuino L, Graber CJ, Miller A, et al. (2008) The arginine
catabolic mobile element and staphylococcal chromosomal cassette mec linkage:
convergence of virulence and resistance in the USA300 clone of methicillin-
resistant Staphylococcus aureus. J Infect Dis 197: 1523–1530.
47. Deurenberg RH, Stobberingh EE (2009) The molecular evolution of hospital-
and community-associated methicillin-resistant Staphylococcus aureus. Curr Mol
Med 9: 100–115.
48. Simpson EH (1949) Measurement of species diversity. Nature 163: 688.
49. Aires de Sousa M, Bartzavali C, Spiliopoulou I, Sanches IS, Crisostomo MI, et
al. (2003) Two international methicillin-resistant Staphylococcus aureus clones
endemic in a university hospital in Patras, Greece. J Clin Microbiol 41:
2027–2032.
50. Grundmann H, Aanensen DM, van den Wijngaard CC, Spratt BG, Harmsen D,
et al. (2010) Geographic distribution of Staphylococcus aureus causing invasive
infections in Europe: a molecular-epidemiological analysis. PLoS Med 7:
e1000215.
51. Lozano C, Gomez-Sanz E, Benito D, Aspiroz C, Zarazaga M, et al. (2011)
Staphylococcus aureus nasal carriage, virulence traits, antibiotic resistance
mechanisms, and genetic lineages in healthy humans in Spain, with detection
of CC398 and CC97 strains. Int J Med Microbiol 301: 500–505.
52. Skramm I, Moen AE, Bukholm G (2011) Nasal carriage of Staphylococcus aureus:
frequency and molecular diversity in a randomly sampled Norwegian
community population. APMIS 119: 522–528.
53. Kanerva M, Salmenlinna S, Vuopio-Varkila J, Lehtinen P, Mottonen T, et al.
(2009) Community-associated methicillin-resistant Staphylococcus aureus isolated in
Finland in 2004 to 2006. J Clin Microbiol 47: 2655–2657.
54. Carpaij N, Willems RJ, Rice TW, Weinstein RA, Hinds J, et al. (2011) Genetic
variation in spatio-temporal confined USA300 community-associated MRSA
isolates: a shift from clonal dispersion to genetic evolution? PLoS One 6: e16419.
55. Larsen AR, Goering R, Stegger M, Lindsay JA, Gould KA, et al. (2009) Two
distinct clones of methicillin-resistant Staphylococcus aureus (MRSA) with the same
USA300 pulsed-field gel electrophoresis profile: a potential pitfall for
identification of USA300 community-associated MRSA. J Clin Microbiol 47:
3765–3768.
56. Highlander SK, Hulten KG, Qin X, Jiang H, Yerrapragada S, et al. (2007)
Subtle genetic changes enhance virulence of methicillin resistant and sensitive
Staphylococcus aureus. BMC Microbiol 7: 99.
57. Nubel U, Roumagnac P, Feldkamp M, Song JH, Ko KS, et al. (2008) Frequent
emergence and limited geographic dispersal of methicillin-resistant Staphylococcus
aureus. Proc Natl Acad Sci U S A 105: 14130–14135.
58. Aires de Sousa M, Conceicao T, Simas C, de Lencastre H (2005) Comparison of
genetic backgrounds of methicillin-resistant and -susceptible Staphylococcus aureus
isolates from Portuguese hospitals and the community. J Clin Microbiol 43:
5150–5157.
59. Conceicao T, Aires-de-Sousa M, Pona N, Brito MJ, Barradas C, et al. (2011)
High prevalence of ST121 in community-associated methicillin-susceptible
Staphylococcus aureus lineages responsible for skin and soft tissue infections in
Portuguese children. Eur J Clin Microbiol Infect Dis 30: 293–297.
60. Issartel B, Tristan A, Lechevallier S, Bruyere F, Lina G, et al. (2005) Frequent
carriage of Panton-Valentine leucocidin genes by Staphylococcus aureus isolates
from surgically drained abscesses. J Clin Microbiol 43: 3203–3207.
61. Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, et al. (2002) Association
between Staphylococcus aureus strains carrying gene for Panton-Valentine
leukocidin and highly lethal necrotising pneumonia in young immunocompetent
patients. Lancet 359: 753–759.
62. Francis JS, Doherty MC, Lopatin U, Johnston CP, Sinha G, et al. (2005) Severe
community-onset pneumonia in healthy adults caused by methicillin-resistant
Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect
Dis 40: 100–107.
63. Loffler B, Hussain M, Grundmeier M, Bruck M, Holzinger D, et al. (2010)
Staphylococcus aureus Panton-Valentine leukocidin is a very potent cytotoxic factor
for human neutrophils. PLoS Pathog 6: e1000715.
64. Tseng CW, Kyme P, Low J, Rocha MA, Alsabeh R, et al. (2009) Staphylococcus
aureus Panton-Valentine leukocidin contributes to inflammation and muscle
tissue injury. PLoS One 4: e6387.
CA-MRSA in Europe
PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e34768